Cancer risk slightly higher among patients treated with abatacept

Although the risks for specific cancers and infections were similar between abatacept and other biologic and targeted synthetic DMARDs among patients with rheumatoid arthritis, a slight increase in total cancer risk associated with the drug requires additional research, according to data published in Arthritis Research & Therapy.“Clinical trials are smaller and include a select

Read the full article here

Related Articles